^
Association details:
| Biomarker: | FGFR2 mutation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Excerpt:
...all of the FGFR2- and FGFR3-mutated cell lines, except 2 and 1, respectively, were growth inhibited by NVP-BGJ398, in line with its ability to effectively block FGFR downstream signaling in the 6 FGFR-mutated cell lines tested (Supplementary Fig. S2). Of note, all FGFR2- and FGFR3-mutant lines belong to the endometrial and multiple myeloma cancer types, respectively...
DOI:
10.1158/2159-8290.CD-12-0210
